Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: succinic acid; sodium hydroxide; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: succinic acid; water for injections; sodium hydroxide - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 200 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 50 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store canada - 16.7 ml glass vial x 1 (100 mg/16.7 ml) - injection - 6 mg/ml - malignant disease,immunosuppresion-cytotoxics

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: glycerol; hydrochloric acid; water for injections - canada idarubicin alone or in combination with other anticancer drugs are used in the treatment of: ? acute non-lymphocytic leukaemia as a first line treatment in adults ? acute lymphocytic leukaemia as a second line in adults and children france zavedos solution for infusion is indicated for the treatment of acute myeloid leukemia. zavedos solution for infusion is indicated for the treatment of acute lymphoblastic leukemia in relapse. germany adults zavedos is indicated for use in combination with other cytostatics (such as cytabarine) for the treatment (remission induction and consolidation) of adult patients with acute myeloid leukaemia (aml, anll) who have not received any previous treatment. children and adolescents zavedos, in combination with cytarabine, is indicated for first-line remission induction treatment of children with blood cancer, called acute myeloid leukaemia (aml), who have not received any previous treatment. netherlands adults acute myeloblastic leukaemia (aml): for remission induction as first line treatment or for remission induction in relapsed or refractory patients. acute lymphoblastic leukaemia (all): second line treatment. children acute myeloblastic leukaemia (aml): for remission induction as first line treatment, in combination with cytarabine. acute lymphoblastic leukaemia (all): second line treatment. switzerland acute myeloid leukaemia in combination with other cytostatics. acute lymphatic leukaemia as reserve medication in combination with other cytostatics.